ReNeuron Group PLC (LON:RENE)

ReNeuron Group PLC (LON:RENE)


Share Price
238.00 p
Change
-6 (-2.46 %)
Market Cap
£75.69 m
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

EPIC: RENE
Market: LSE:RENE
FRA:RQE1
52-week High/Low: 342.00p / 29.50p
Sector: Pharma & Biotech
Market Cap: £75.69 m
Website: www.reneuron.com
col 3
col 4
col 5
col 6

ReNeuron Group PLC RNS Announcements

Date Epic Announcement
17/07/2019 RENE Director/PDMR Interest in Shares & Share Options
16/07/2019 RENE Key patent grants expand exosome IP portfolio
12/07/2019 RENE Senior business development appointment
11/07/2019 RENE Preliminary Results
08/07/2019 RENE Notification of Major Holdings
01/07/2019 RENE Price Monitoring Extension
01/07/2019 RENE Total Voting Rights
18/06/2019 RENE Notification of Major Holdings
18/06/2019 RENE Webcast of Preliminary Results
14/06/2019 RENE ReNeuron wins Breakthrough of the Year Award
03/06/2019 RENE Total Voting Rights
31/05/2019 RENE Jefferies 2019 Global Healthcare Conference
09/05/2019 RENE Exercise of options, PDMR dealing and TVR
08/05/2019 RENE Year-end update and results notification
02/05/2019 RENE Total Voting Rights
26/04/2019 RENE Second Price Monitoring Extn
26/04/2019 RENE Price Monitoring Extension
26/04/2019 RENE Clinical update and conference presentation
18/04/2019 RENE Share Purchases by Directors
12/04/2019 RENE Exercise of Share Options and TVR
11/04/2019 RENE Share Purchases by Directors
10/04/2019 RENE Director/PDMR Shares and Share Options
09/04/2019 RENE ReNeuron partners with Fosun Pharma in China
05/04/2019 RENE ReNeuron to present at UK investor conference
04/04/2019 RENE Clinical update and conference presentation
28/03/2019 RENE Second Price Monitoring Extn
28/03/2019 RENE Price Monitoring Extension
18/03/2019 RENE Alliance for Regenerative Medicine presentation
18/03/2019 RENE Retinal clinical trial progresses to next stage
12/03/2019 RENE Notification of Major Holdings

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use